Portola Pharmaceuticals' experimental Factor Xa inhibitor antidote andexanet alfa has won breakthrough therapy designation from the FDA. The drug is designed for patients who need emergency surgery or who experience uncontrolled bleeding after taking Factor Xa inhibitors such as apixaban and rivaroxaban. The firm said it would seek an accelerated approval pathway for the drug and could start registration-enabling trials next year.

Related Summaries